Company intelligence / Profile preview

XO1

London, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

XO1 developed a synthetic antibody, ichorcumab, which targets thrombin with the goal to provide anticoagulation without increased bleeding risk; strong preclinical animal data were generated, but no clinical results reported before acquisition by Janssen

Therapeutic areas: HematologyCardiovascularNeurology
Modalities: Monoclonal antibody
Industry: Biotech

Partnerships

Index VenturesUniversity of CambridgeLonza

Beyond the preview

Go deeper on XO1.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XO1.

Explore the full profile